BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會


Laura Matz

Session 1 (Plenary) – Global Biotech Development

Date:27 July (Wednesday)
Time:  09:00 – 10:30 (GMT+8)

Laura Matz

Chief Science and Technology Officer
Merck, KGaA, Darmstadt, Germany

Dr. Laura Matz is the Chief Science and Technology Officer for Merck, driving innovation and digitalization in Merck across the 3 business sectors, Life Sciences, Healthcare and Electronics. Serving as an executive vice-president within Merck, her areas of responsibility include Digital, Enterprise Data, Future Insight, as well as the company’s global innovation hubs in China, Israel, the U.S. and at its Darmstadt HQ. In addition, Laura is CEO for the newly launched data sharing platform company, Athinia, which is focused on enabling data sharing within the semiconductor ecosystem. Laura joined Merck, KGaA Darmstadt, Germany in 2019 through the acquisition of Versum Materials.  

She possesses 20 years of experience in semiconductor manufacturing and a decade of experience running semiconductor materials businesses. Prior to moving to the CSTO role, she served as Head of Planarization in the semiconductor materials business while also heading a sector-wide digital program for quality innovation with the company’s electronics customers. Laura started at Versum Materials in 2016, having previously worked at Air Products and Texas Instruments. 

Laura is a strong advocate for science and engineering in young talent.  She has collaborated with ASU over the past 5 years to build a strong pipeline of interns. In 2020, Laura joined the AICHE (American Institute of Chemical Engineers) ILI board (Institute for Learning and Innovation) which serves as a conduit for advancing chemical engineering talent for the U.S. Given that artificial intelligence and machine learning are enablers for the continued growth in the semiconductor industry, she is a member of the SEMI Smart Manufacturing board as well as the local AZ SEMI board.  

Laura has a PhD in analytical chemistry from Washington State University and undergraduate degree from Indiana University of Pennsylvania.  

Speech title & Synopsis

Bioconvergence: Potential Future Impacts to Personalized Medicine

Nature has long been at the core of modern science. Then materials, structures, and processes that provide organisms with their functionality and behaviors have contributed to countless discoveries from gravity through to DNA. The lines between traditional scientific disciplines are however becoming increasingly blurred as data and digital technologies collide with material sciences and biotechnology. Bioconvergence represents a new, multi-disciplinary approach to improve the speed and impact of scientific discovery. 

Operating at the intersection between the natural and formal sciences, it unifies the latest theories, processes, and products in life science, healthcare, and electronics to enhance human health and well-being. In healthcare, advances in artificial​ intelligence (AI) and machine learning (ML) are resulting in an exponential increase in our ability to harness biological and clinical data from experimental to real-world settings. One example is translational Medicine, which relies on quantitative integration powered by multiple advanced analytical solutions to support forward and reverse translation. Here, the focus is to build confidence in the central pillars of translational medicine: target, patient, and dose thriving for clinical development that is broadly inclusive and unbiased and at the same time ensures patient centricity and safety. 

To enable personalized medicine, collaboration will play an important role addressing the need to combine various competencies and technologies. By focusing more on prevention, early detection, and responsive remote treatment we envision to live longer, healthier, and more sustainably.